دورية أكاديمية
Pre-Delta, Delta, and Omicron Periods of the Coronavirus Disease 2019 (COVID-19) Pandemic and Health Outcomes During Delivery Hospitalization.
| العنوان: | Pre-Delta, Delta, and Omicron Periods of the Coronavirus Disease 2019 (COVID-19) Pandemic and Health Outcomes During Delivery Hospitalization. |
|---|---|
| المؤلفون: | Carlson J; Eagle Global Scientific, LLC, and the Division of Birth Defects and Infant Disorders, the Coronavirus and Other Respiratory Viruses Division, the Influenza Division, the Division of Reproductive Health, and the Division of Viral Disease, Centers for Disease Control and Prevention, Atlanta, Georgia; and Weill Cornell Medicine, New York, New York., Simeone RM, Ellington S, Galang R, DeSisto CL, Fleming-Dutra K, Riley L, Meaney-Delman D, Tong VT |
| المصدر: | Obstetrics and gynecology [Obstet Gynecol] 2024 Jan 01; Vol. 143 (1), pp. 131-138. Date of Electronic Publication: 2023 Nov 02. |
| نوع المنشور: | Observational Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401101 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-233X (Electronic) Linking ISSN: 00297844 NLM ISO Abbreviation: Obstet Gynecol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York. |
| مواضيع طبية MeSH: | COVID-19*/epidemiology , Pregnancy Complications, Infectious*/epidemiology, Pregnancy ; Infant, Newborn ; Female ; Humans ; SARS-CoV-2 ; COVID-19 Testing ; Cross-Sectional Studies ; Hospital Mortality ; Pandemics ; Hospitalization ; Outcome Assessment, Health Care |
| مستخلص: | Objective: To examine the relationship between coronavirus disease 2019 (COVID-19) diagnosis at delivery and adverse maternal health and pregnancy outcomes during pre-Delta, Delta, and Omicron variant predominance, with a focus on the time period of Omicron variant predominance. Methods: We conducted a cross-sectional observational study with data from delivery hospitalizations in the Premier Healthcare Database from February 2020 to August 2023. The pre-Delta (February 2020-June 2021), Delta (July 2021-December 2021), and Omicron (January 2022-August 2023) periods of variant predominance were examined. Exposure to COVID-19 was identified by having a diagnostic code for COVID-19 during the delivery hospitalization. Adjusted prevalence ratios (aPRs) were calculated to compare the risks of adverse maternal and pregnancy outcomes for women with and without COVID-19 diagnoses at the time of delivery for each variant period. Results: Among 2,990,973 women with delivery hospitalizations, 1.9% (n=56,618) had COVID-19 diagnoses noted at delivery admission discharge, including 26,053 during the Omicron period. Across all variant time periods, the prevalence of many adverse maternal and pregnancy outcomes during the delivery hospitalization was significantly higher for pregnant women with COVID-19 compared with pregnant women without COVID-19. In adjusted models, COVID-19 during the Omicron period was associated with significant increased risks for maternal sepsis (COVID-19: 0.4% vs no COVID-19: 0.1%; aPR 3.32, 95% CI, 2.70-4.08), acute respiratory distress syndrome (0.6% vs 0.1%; aPR 6.19, 95% CI, 5.26-7.29), shock (0.2% vs 0.1%; aPR 2.14, 95% CI, 1.62-2.84), renal failure (0.5% vs 0.2%; aPR 2.08, 95% CI, 1.73-2.49), intensive care unit admission (2.7% vs 1.7%; aPR 1.64, 95% CI, 1.52-1.77), mechanical ventilation (0.3% vs 0.1%; aPR 3.15, 95% CI, 2.52-3.93), in-hospital death (0.03% vs 0.01%; aPR 5.00, 95% CI, 2.30-10.90), stillbirth (0.7% vs 0.6%; aPR 1.17, 95% CI, 1.01-1.36), and preterm delivery (12.3% vs 9.6%; aPR 1.28, 95% CI, 1.24-1.33). Conclusion: Despite the possibility of some level of immunity due to previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or testing differences, risks of adverse outcomes associated with COVID-19 diagnosis at delivery remained elevated during the Omicron variant time period. Competing Interests: Financial Disclosure Regina M. Simeone disclosed previously owning Pfizer stock. Jeffrey Carlson disclosed previously owning Moderna stock. Laura Riley disclosed being an author for Up to Date (HSV, Rubella, Parvovirus), consultant to GSK and Pfizer, and consulted on Medscape education module. The other authors did not report any potential conflicts of interest. (Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Lancet Reg Health Eur. 2023 Mar;26:100569. (PMID: 36628358) Obstet Gynecol Clin North Am. 2023 Jun;50(2):279-297. (PMID: 37149310) Obstet Gynecol. 2022 Aug 1;140(2):262-265. (PMID: 35852277) MMWR Morb Mortal Wkly Rep. 2023 Jun 02;72(22):601-605. (PMID: 37262007) MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645. (PMID: 34818318) MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):657-662. (PMID: 37319020) BMJ. 2022 Feb 11;376:o358. (PMID: 35149516) Lancet. 2023 Feb 11;401(10375):447-457. (PMID: 36669520) JAMA Netw Open. 2022 Sep 1;5(9):e2233273. (PMID: 36156146) J Infect Chemother. 2023 Jan;29(1):33-38. (PMID: 36103949) J Perinatol. 2022 May;42(5):617-623. (PMID: 35169228) BMJ. 2020 Sep 1;370:m3320. (PMID: 32873575) Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S24-S31. (PMID: 33977298) Lancet Respir Med. 2022 Dec;10(12):1129-1136. (PMID: 36216011) MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):206-211. (PMID: 35143464) JAMA Netw Open. 2023 Feb 1;6(2):e231181. (PMID: 36853602) Ultrasound Obstet Gynecol. 2022 Jul;60(1):96-102. (PMID: 35441407) MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1641-1647. (PMID: 33151921) Am J Infect Control. 2023 Mar;51(3):351-353. (PMID: 35921943) MMWR Morb Mortal Wkly Rep. 2022 Dec 02;71(48):1526-1530. (PMID: 36454688) MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1182-1189. (PMID: 36107788) MMWR Morb Mortal Wkly Rep. 2023 May 12;72(19):523-528. (PMID: 37167154) Am J Obstet Gynecol MFM. 2022 Nov;4(6):100712. (PMID: 35970495) MMWR Morb Mortal Wkly Rep. 2023 Apr 28;72(17):463-468. (PMID: 37104244) |
| معلومات مُعتمدة: | CC999999 United States ImCDC Intramural CDC HHS |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20231102 Date Completed: 20231216 Latest Revision: 20240320 |
| رمز التحديث: | 20240320 |
| مُعرف محوري في PubMed: | PMC10949122 |
| DOI: | 10.1097/AOG.0000000000005449 |
| PMID: | 37917932 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!